HC Wainwright set a $21.00 price objective on Sol Gel Technologies (NASDAQ:SLGL) in a report issued on Wednesday morning, TipRanks reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Sol Gel Technologies from a hold rating to a buy rating and set a $7.25 price objective on the stock in a report on Tuesday, February 12th. ValuEngine lowered shares of Sol Gel Technologies from a buy rating to a hold rating in a report on Friday, December 21st.

NASDAQ SLGL opened at $7.15 on Wednesday. Sol Gel Technologies has a 12-month low of $5.41 and a 12-month high of $10.24. The firm has a market capitalization of $139.61 million, a price-to-earnings ratio of -3.97 and a beta of 0.82.

Sol Gel Technologies (NASDAQ:SLGL) last released its quarterly earnings results on Thursday, March 21st. The company reported ($1.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.82). Sol Gel Technologies had a negative return on equity of 58.33% and a negative net margin of 20,190.54%. The firm had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.05 million. As a group, sell-side analysts anticipate that Sol Gel Technologies will post -1.99 EPS for the current fiscal year.

A hedge fund recently raised its stake in Sol Gel Technologies stock. Delek Group Ltd. increased its stake in shares of Sol Gel Technologies Ltd (NASDAQ:SLGL) by 9.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,429,761 shares of the company’s stock after buying an additional 128,796 shares during the quarter. Delek Group Ltd. owned about 7.56% of Sol Gel Technologies worth $8,838,000 as of its most recent SEC filing. Institutional investors and hedge funds own 21.07% of the company’s stock.

About Sol Gel Technologies

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.

Featured Story: Why are analyst ratings important in trading stocks?

Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.